IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
Lee KJ, Choi D, Tae N, Song HW, Kang YW, Lee M, Moon D, Oh Y, Park S, Kim JH, Jeong S, Yang J, Park U, Hong DH, Byun MS, Park SH, Sohn J, Park Y, Im SK, Choi SS, Kim DH, Lee SW.
Lee KJ, et al. Among authors: im sk.
Cell Rep Med. 2024 May 21;5(5):101567. doi: 10.1016/j.xcrm.2024.101567. Epub 2024 May 13.
Cell Rep Med. 2024.
PMID: 38744277
Free PMC article.